Compare CSX Corporation (CSX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Moderna, Inc. — how do they compare? CSX Corporation trades at $47.6 (market cap $86.70B), while Moderna, Inc. trades at $195.81 (market cap $78.44B). The key difference: CSX Corporation and Moderna, Inc. are close in size by market cap, and CSX Corporation pays a 1.2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Moderna, Inc. for 59 Days on average.
| CSX | MRNA | |
|---|---|---|
Market Cap | $86.70B | $78.44B |
Volume | 6,811,485 | 14,597,511 |
Sector | Industrials | Health |
52-Week High | $53.21 | $203.46 |
52-Week Low | $33.68 | $22.36 |
Typical Hold Time | 55 Days | 59 Days |
Enterprise Value | $104.66B | $74.59B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $46.81, down 1.45% today, with a bearish technical signal from moving averages. The company reported mixed quarterly EPS results, missing in Q4 2025 but beating in Q1 and Q2 2026. Revenue has declined from $14.9B in 2022 to $14.1B in 2025, though 2026 projections show a rebound to $14.5B. Analyst consensus is bullish with a $51 price target, supported by strong institutional buying activity reported in recent SEC filings.
The outlook for CSX hinges on earnings recovery and operational efficiency gains. Key opportunities include pricing power in freight rail and dividend growth, while risks involve revenue volatility and high debt levels. The stock offers potential upside to the consensus target but faces headwinds from economic cycles affecting freight demand.
Moderna (MRNA) trades at $196.48, up 4.81% amid Nasdaq-100 inclusion news, though it remains well below the analyst consensus target of $115.70. The stock shows bullish technical momentum with recent earnings beats, but faces fundamental challenges with negative profit margins and declining revenue from pandemic-era highs. The company's cash flow improved in 2025, turning positive for the first time since 2022, while its pipeline, including oncology vaccines, attracts investor interest despite valuation concerns.
Outlook: Near-term momentum from index fund buying and pipeline updates may support the stock, but high valuation multiples and persistent losses pose significant risks. Long-term growth depends on successful commercialization of non-COVID products, with current prices reflecting optimistic scenarios. Investors should weigh the potential of the mRNA platform against execution risks and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
